Click here for slides on this topic


Prospective Pioglitazone Clinical Trial in Macrovascular Events (PRO active) study

Multicenter, double-blind, placebo-controlled, randomized study designed to investigate whether the addition of pioglitazone to the usual medication regimen of the high-risk patient with type 2 diabetes and cardiovascular disease (CVD) can reduce total mortality and macrovascular morbidity.
The following content matched the glossary term: Prospective Pioglitazone Clinical Trial in Macrovascular Events (PRO active) study

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive

Top

Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; on behalf of the PROactive investigators. Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive. Drug Saf. 2009;32(3):187-202. People with type 2 diabetes mellitus have an excess risk of macrovascular disease and a poorer prognosis. PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) was a landmark study of secondary cardiovascular disease (CVD) prevention in type 2 diabetes that suggested a beneficial effect of pioglitazone therapy on macrovascular outcomes.

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROactive 10.

Top

Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008;155(4):712-7. Epub 2008 Feb 21. Composite end points of major adverse cardiovascular events (MACEs) are standard measures for comparing treatment in large cardiovascular outcome studies.

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

Top

Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19(1):182-7. Patients with diabetes and chronic kidney disease (CKD) are at particularly high risk for cardiovascular disease (CVD).

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients w type 2 diabetes & previous myocardial infarction: from PROactive Study

Top

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772-80. This analysis from the PROactive (PROspective pioglitAzone macroVascular Events) study assesses the effects of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes and a previous myocardial infarction (MI).

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive

Top

Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865-873. Diabetes is an important risk factor for stroke. We conducted analyses in patients who had entered the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) with a history of stroke or without stroke.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study

Top

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289. Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes.

Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial

Top

Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253-260. To evaluate the effect of case management by a clinical pharmacist on glycemic control and preventive measures in patients with type 2 diabetes mellitus.

The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes?

Top

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A.. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care. 2004;27:1647-1653. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) assesses the effect of pioglitazone, a peroxisome proliferator-activated receptor agonist, with anti-inflammatory and vascular properties, on the secondary prevention of macrovascular events in type 2 diabetes.



Slide Library Results

Search Results for: Prospective Pioglitazone Clinical Trial in Macrovascular Events (PRO active) study Slides Found: 0